Gene therapy injection aims to halt blindness from rare eye disorder

NCT ID NCT06699108

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 trial tests a gene therapy called VGR-R01 for Bietti crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The study will enroll 45 adults who receive either the gene therapy injection under the retina or a control treatment. Researchers will measure changes in visual acuity over time to see if the therapy can preserve or improve sight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VGR-R01 (gene therapy given as an injection under the retina)
What this could lead to
If it works, this could point toward a treatment that slows or stops vision loss in people with Bietti crystalline dystrophy.
What could go wrong
This is an early-stage Phase 3 trial with only 45 people, so results may not apply to everyone. Gene therapy carries risks like eye infection or inflammation, and it may not improve vision.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIETTI CRYSTALLINE DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Vitalgen Biopharma Co.,Ltd.

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.